Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells

Journal of Bone and Mineral Research

Volumn 31, Issue 10, 2016, Pages 1877-1887

  Rauner, Martina ^a   Franke, Kristin ^a   Murray, Marta ^a   Singh, Rashim Pal ^a   Hiram Bab, Sahar ^b   Platzbecker, Uwe ^a   Gassmann, Max ^c,d   Socolovsky, Merav ^e   Neumann, Drorit ^b   Gabet, Yankel ^b   Chavakis, Triantafyllos ^a,f   Hofbauer, Lorenz C ^a,f   Wielockx, Ben ^a,f  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

BONE LOSS; ERYTHROPOIETIN; OSTEOBLAST; OSTEOCLAST; PHD2

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE 2; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; EGLN1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE STRUCTURE; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; HEMATOPOIETIC CELL; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRABECULAR BONE; ANIMAL; BIOSYNTHESIS; BONE MARROW; DEFICIENCY; GENETICS; HEMATOPOIETIC STEM CELL; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; BONE DENSITY; BONE MARROW; BONE RESORPTION; ERYTHROPOIETIN; HEMATOPOIETIC STEM CELLS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MICE; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS;

EID: 84970005909     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2857     Document Type: Article

References (42)

1. Marie PJ. Signaling pathways affecting skeletal health. Curr Osteoporos Rep. 2012; 10(3):190–8.
2. Dirckx N, Van Hul M, Maes C. Osteoblast recruitment to sites of bone formation in skeletal development, homeostasis, and regeneration. Birth Defects Res C Embryo Today. 2013; 99(3):170–91.
3. Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011; 165(1):1–10.
4. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011; 377(9773):1276–87.
5. Bentovim L, Amarilio R, Zelzer E. HIF1alpha is a central regulator of collagen hydroxylation and secretion under hypoxia during bone development. Development. 2012; 139(23):4473–83.
6. van Patot MCT, Gassmann M. Hypoxia: adapting to high altitude by mutating EPAS-1, the gene encoding HIF-2a. High Alt Med Biol. 2011; 12(2):157–67.
7. Hu C-J., Wang L-Y., Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003; 23(24):9361–74.
8. Fandrey J, Gorr TA, Gassmann M. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res. 2006; 71(4):642–51.
9. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2010; 6:165–92.
10. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005; 105(8):3133–40.
11. Takubo K, Goda N, Yamada W, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010; 7(3):391–402.
12. Singh RP, Franke K, Kalucka J, et al. HIF prolyl hydroxylase 2 (PHD2) is a critical regulator of hematopoietic stem cell maintenance during steady-state and stress. Blood. 2013; 121(26):5158–66.
13. Franke K, Kalucka J, Mamlouk S, et al. HIF-1alpha is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2alpha-induced excessive erythropoiesis. Blood. 2013; 121(8):1436–45.
14. Gassmann M, Muckenthaler MU. Adaptation of iron requirement to hypoxic conditions at high altitude. J Appl Physiol (1985). 2015 Dec 15; 119(12):1432–40.
15. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001; 15(7):1312–4.
16. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011; 364(7):656–65.
17. Laitala A, Aro E, Walkinshaw G, et al. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood. 2012; 120(16):3336–44.
18. Mamlouk S, Wielockx B. Hypoxia-inducible factors as key regulators of tumor inflammation. Int J Cancer. 2013; 132(12):2721–9.
19. Singh RP, Franke K, Wielockx B. Hypoxia-mediated regulation of stem cell fate. High Alt Med Biol. 2012; 13(3):162–8.
20. Franke K, Gassmann M, Wielockx B. Erythrocytosis: the HIF pathway in control. Blood. 2013; 122(7):1122–8.
21. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006; 26(22):8336–46.
22. Ruschitzka FT, Wenger RH, Stallmach T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A 2000; 97(21):11609–13.
23. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133(16):3231–44.
24. Stadtfeld M, Graf T. Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. Development. 2005; 132(1):203–13.
25. Thiele S, Ziegler N, Tsourdi E, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res. 2012; 27(11):2242–50.
26. Rauner M, Thiele S, Sinningen K, et al. Effects of the selective glucocorticoid receptor modulator compound A on bone metabolism and inflammation in male mice with collagen-induced arthritis. Endocrinology. 2013; 154(10):3719–28.
27. Rauner M, Foger-Samwald U, Kurz MF, et al. Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. Bone. 2014; 64:281–7.
28. Stegen S, van Gastel N, Eelen G, et al. HIF-1alpha promotes glutamine-mediated redox homeostasis and glycogen-dependent bioenergetics to support postimplantation bone cell survival. Cell Metab. 2016; 23(2):265–79.
29. Rankin E, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012; 149(1):63–74.
30. Maes C, Kobayashi T, Selig MK, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell. 2010; 19(2):329–44.
31. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One. 2014; 9(1):e85161.
32. Singbrant S, Russell MR, Jovic T, et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood. 2011; 117(21):5631–42.
33. Hiram-Bab S, Liron T, Deshet-Unger N, et al. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB.J. 2015; 29(5):1890–900.
34. Shiozawa Y, Jung Y, Ziegler AM, et al. Erythropoietin couples hematopoiesis with bone formation. PLoS One. 2010; 5(5):e10853.
35. Ogunshola OO, Bogdanova AY. Epo and non-hematopoietic cells: what do we know? Methods Mol Biol. 2013; 982:13–41.
36. Mamlouk S, Kalucka J, Singh RP, et al. Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. Int J Cancer. 2014; 134(4):849–58.
37. Cheng S, Xing W, Pourteymoor S, Mohan S. Conditional disruption of the prolyl hydroxylase domain-containing protein 2 (Phd2) gene defines its key role in skeletal development. J Bone Miner Res. 2014; 29(10):2276–86.
38. Florin L, Alter H, Grone HJ, Szabowski A, Schutz G, Angel P. Cre recombinase-mediated gene targeting of mesenchymal cells. Genesis. 2004; 38(3):139–44.
39. Wu C, Rankin EB, Castellini L, et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev. 2015; 29(8):817–31.
40. Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007; 117(6):1616–26.
41. Wan C, Gilbert SR, Wang Y, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A. 2008; 105(2):686–91.
42. Roberts BE, Woods CG, Miles DW, Paterson CR. Bone changes in polycythaemia vera and myelosclerosis. J Clin Pathol. 1969; 22(6):696–700.